Abstract
OBJECTIVE Neurological complications can worsen outcomes in COVID-19. We defined the prevalence of a wide range of neurological conditions among patients hospitalized with COVID-19 in geographically diverse multinational populations.
METHODS Using electronic health record (EHR) data from 348 participating hospitals across 6 countries and 3 continents between January and September 2020, we performed a cross-sectional study of hospitalized adult and pediatric patients with a positive SARS-CoV-2 reverse transcription polymerase chain reaction test, both with and without severe COVID-19. We assessed the frequency of each disease category and 3-character International Classification of Disease (ICD) code of neurological diseases by countries, sites, time before and after admission for COVID-19, and COVID-19 severity.
RESULTS Among the 35,177 hospitalized patients with SARS-CoV-2 infection, there was increased prevalence of disorders of consciousness (5.8%, 95% confidence interval [CI]: 3.7%-7.8%, pFDR<.001) and unspecified disorders of the brain (8.1%, 95%CI: 5.7%-10.5%, pFDR<.001), compared to pre-admission prevalence. During hospitalization, patients who experienced severe COVID-19 status had 22% (95%CI: 19%-25%) increase in the relative risk (RR) of disorders of consciousness, 24% (95%CI: 13%-35%) increase in other cerebrovascular diseases, 34% (95%CI: 20%-50%) increase in nontraumatic intracranial hemorrhage, 37% (95%CI: 17%-60%) increase in encephalitis and/or myelitis, and 72% (95%CI: 67%-77%) increase in myopathy compared to those who never experienced severe disease.
INTERPRETATION Using an international network and common EHR data elements, we highlight an increase in the prevalence of central and peripheral neurological phenotypes in patients hospitalized with SARS-CoV-2 infection, particularly among those with severe disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AS is funded by NIH-NHLBI K23HL148394 and L40HL148910, and NIH-NCATS UL1TR001420 (NIH-NCATS). JM is funded by NIH-NIAID AI11679. LP is funded by NCATS CTSA Award #UL1TR002366. GO is funded by NIH NIEHS P30ES017885 and NCI U24CA210967. SV is funded by NIH-NLM R01LM012095 and NCATS UL1TR001857. DM is funded by NCATS CTSA Award #UL1-TR001878. ZX is funded by NIH NINDS R01NS098023.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board Approval was obtained by Assistance Publique - Hopitaux de Paris, Erlangen University Hospital, University Medicine Mannheim, Policlinico di Milano, ASST Papa Giovanni XXIII Bergamo, University of Kansas Medical Center, UT Southwestern Medical Center, Northwestern University, The Childrens Hospital of Philadelphia, Great Ormond Street Hospital for Children, Medical College of Wisconsin, University of Alabama at Birmingham, Hospital Universitario 12 de Octubre, Wake Forest School of Medicine & Brenner Childrens Hospital, University Magna Graecia of Catanzaro & Mater Domini University Hospital, Catanzaro, University of Kentucky, VISN1 - VA New England Health Care System, VISN2 - VA Healthcare New York/New Jersey, VISN4 - VISN4 network (PA, DE, NJ, OH), VISN5 - VA Capitol Healthcare Network, VISN6 - VA Mid-Atlantic Health Care Network, VISN7 - VA Southeast Network, VISN8 - VA Sunshine Healthcare Network, VISN9 - VA MidSouth Healthcare Network, VISN10 - VA Healthcare System VISN10, VISN12 - VA Great Lakes Healthcare System, VISN15 - VA Heartland Network, VISN16 - South Central VA Healthcare Network, VISN17 - VA Heart of Texas Healthcare System, VISN18 - VA Southwest Healthcare Network, VISN19 - VA Rocky Mountain Network, VISN20 - VA Northwest Health Network, VISN21 - VA Sierra Pacific Network, VISN22 - VA Desert Pacific Healthcare Network, VISN23 - VA Midwest Healthcare Network, and Universidade Estadual Julio de Mesquita Filho. An IRB Exempt determination was obtained at Bordeaux University Hospital Medical Center, University of Freiburg, Beth Israel Deaconess Medical Center, Mass General Brigham (Partners Healthcare), University of Pennsylvania, University of California, LA, University of Michigan, Boston Childrens Hospital, and University of Pittsburgh / UPMC. An IRB Waiver was obtained by Instituti Clinici Scientifici Maugeri, National University Hospital, Medical University of South Carolina, St. Luke's University Health Network, and Riverside Health System.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The 4CE consortium does not have permission from each individual contributing site to release EHR data for public access. Our analysis results are available in browsable R notebooks (https://github.com/covidclinical/Phase1.1NeuroRCode/) under CC BY 4.0, with source code distributed under a BSD 3-Clause License.
